Main Article Content
Hypothyroidism is an underactive thyroid gland that results in too little thyroid hormones in circulation causing a slowdown in metabolism, therefor hypothyroid modifies physiological process of primary and secondary hemostasis and may lead to a higher bleeding risk.
Objectives: The aim of this study is to assess the coagulation profiles [Prothrombin Time (PT), International Normalize Ratio (INR), Activated Partial Thromboplastin Time (PTT)] in patients with hypothyroidism.
Methodology: This is a case-control hospital-based study carried out at the National Cancer Institute – University of Gezira (NCI-UG), Wad Medani, Sudan from January to October 2020. A total of 100 (50 patients with hypothyroidism as cases (38.50 ± 10.46 years) matched with 50 normal healthy individuals as controls (35.52 ± 11.64 years) participated in this study. Two ml of venous blood sample was collected in a trisodium citrate container. Coagulation profiles (PT, INR, and PTT) were measured using a Coatron M4 coagulometer. SPSS computer program (v 21.0) was used for data analysis.
Results: The prolonged PTT account for 74%. The average PTT of cases (42.29 ± 7.22 sec) was higher than controls (32.67 ± 5.90 sec) giving highly statistically significant differences (P value = 0.000) between them. There were significant differences in PTT between mild and severe hypothyroidism (P value = 0.0470). PTT had significant positive correlation within TSH (P value = 0.048; r = 0.070) and significant negative correlation within T3 (P value = 0.000; r = - 0.490) and T4 (P value = 0.020; r = - 520; P value = 000).
Conclusion: The study concluded that PTT was significantly higher in a patient with hypothyroidism when compared to the control. PTT results showed there was a significant negative correlation between T3 and T4 levels and a significant positive correlation with TSH levels. So, PTT should be included as a follow-up routine test for patients with hypothyroidism.
Keywords: Prothrombin time, International Normalized Ratio, Partial Thromboplastin Time, Hypothyroidism, Sudan.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The journal allows the author(s) to hold the copyright without restrictions and will retain publishing rights without restrictions.
The submitted papers are assumed to contain no proprietary material unprotected by patent or patent application; responsibility for technical content and for protection of proprietary material rests solely with the author(s) and their organizations and is not the responsibility of the journal. The main (first/corresponding) author is responsible for ensuring that the article has been seen and approved by all the other authors. It is the responsibility of the author to obtain all necessary copyright release permissions for the use of any copyrighted materials in the manuscript prior to the submission.
What are my rights as an author?
It is important to check the policy for the journal to which you are submitting or publishing to establish your rights as
Author. Journal's standard policies allow the following re-use rights:
- The journal allows the author(s) to hold the copyright without restrictions.
- The journal allows the author(s) to obtain publishing rights without restrictions.
- You may do whatever you wish with the version of the article you submitted to the journal.
- Once the article has been accepted for publication, you may post the accepted version of the article on your own personal website, your department's website or the repository of your institution without any restrictions.
- You may not post the accepted version of the article in any repository other than those listed above (i.e. you may not deposit in the repository of another institution or a subject-matter repository) until 12 months after publication of the article in the journal.
- You may use the published article for your own teaching needs or to supply on an individual basis to research colleagues, provided that such supply is not for commercial purposes.